AUSTEDO XR

Teva Pharmaceuticals presented positive real-world data on AUSTEDO XR® for tardive dyskinesia (TD) at the 2025 Psych Congress. A survey of 209 TD patients showed significant treatment satisfaction, with over 94% reporting movement improvement and over 89% expressing high overall satisfaction. Furthermore, 77% reported improved social comfort and emotional well-being, and 96% found the medication easy to take. 96% of patients expressed interest in continuing treatment.